JP6991585B2 - メニン阻害剤としてのピペリジン - Google Patents

メニン阻害剤としてのピペリジン Download PDF

Info

Publication number
JP6991585B2
JP6991585B2 JP2018557418A JP2018557418A JP6991585B2 JP 6991585 B2 JP6991585 B2 JP 6991585B2 JP 2018557418 A JP2018557418 A JP 2018557418A JP 2018557418 A JP2018557418 A JP 2018557418A JP 6991585 B2 JP6991585 B2 JP 6991585B2
Authority
JP
Japan
Prior art keywords
group
alkyl
optionally substituted
pharmaceutically acceptable
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2018557418A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019514950A (ja
JP2019514950A5 (cg-RX-API-DMAC7.html
Inventor
シャオメン ワン
アンジェロ アギラー
ケ チャン
シリン スー
ティアンフェン スー
デンジル ベルナード
リュー フアン
Original Assignee
ザ リージェンツ オブ ザ ユニヴァシティ オブ ミシガン
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ザ リージェンツ オブ ザ ユニヴァシティ オブ ミシガン filed Critical ザ リージェンツ オブ ザ ユニヴァシティ オブ ミシガン
Publication of JP2019514950A publication Critical patent/JP2019514950A/ja
Publication of JP2019514950A5 publication Critical patent/JP2019514950A5/ja
Application granted granted Critical
Publication of JP6991585B2 publication Critical patent/JP6991585B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/34—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2018557418A 2016-05-02 2017-05-02 メニン阻害剤としてのピペリジン Expired - Fee Related JP6991585B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662330350P 2016-05-02 2016-05-02
US62/330,350 2016-05-02
PCT/US2017/030577 WO2017192543A1 (en) 2016-05-02 2017-05-02 Piperidines as menin inhibitors

Publications (3)

Publication Number Publication Date
JP2019514950A JP2019514950A (ja) 2019-06-06
JP2019514950A5 JP2019514950A5 (cg-RX-API-DMAC7.html) 2020-06-18
JP6991585B2 true JP6991585B2 (ja) 2022-01-12

Family

ID=58699299

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018557418A Expired - Fee Related JP6991585B2 (ja) 2016-05-02 2017-05-02 メニン阻害剤としてのピペリジン

Country Status (13)

Country Link
US (2) US10899738B2 (cg-RX-API-DMAC7.html)
EP (1) EP3452461B1 (cg-RX-API-DMAC7.html)
JP (1) JP6991585B2 (cg-RX-API-DMAC7.html)
KR (1) KR20190015275A (cg-RX-API-DMAC7.html)
CN (1) CN109415337B (cg-RX-API-DMAC7.html)
AU (1) AU2017259436B2 (cg-RX-API-DMAC7.html)
BR (1) BR112018072570A2 (cg-RX-API-DMAC7.html)
CA (1) CA3022868A1 (cg-RX-API-DMAC7.html)
ES (1) ES2899936T3 (cg-RX-API-DMAC7.html)
IL (2) IL262697B (cg-RX-API-DMAC7.html)
MX (1) MX384087B (cg-RX-API-DMAC7.html)
SG (1) SG11201809714TA (cg-RX-API-DMAC7.html)
WO (1) WO2017192543A1 (cg-RX-API-DMAC7.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020515571A (ja) * 2017-03-31 2020-05-28 ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン 共有結合性メニン阻害剤としてのピペリジン

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016040330A1 (en) 2014-09-09 2016-03-17 The Regents Of The University Of Michigan Thienopyrimidine and thienopyridine compounds and methods of use thereof
TWI703150B (zh) 2015-06-04 2020-09-01 美商庫拉腫瘤技術股份有限公司 用於抑制ｍｅｎｉｎ及ｍｌｌ蛋白之交互作用的方法及組合物
US10588907B2 (en) 2015-06-04 2020-03-17 Kura Oncology, Inc. Methods and compositions for inhibiting the interaction of menin with MLL proteins
SI3429591T1 (sl) 2016-03-16 2023-07-31 Kura Oncology, Inc. Substituirani tieno(2,3-d)pirimidinski derivati kot inhibitorji menin-MLL in postopki uporabe
PH12018501955B1 (en) 2016-03-16 2024-01-24 Kura Oncology Inc Bridged bicyclic inhibitors of menin-mll and methods of use
WO2017192543A1 (en) 2016-05-02 2017-11-09 Regents Of The University Of Michigan Piperidines as menin inhibitors
JP7007302B2 (ja) 2016-06-10 2022-01-24 ヴァイティー ファーマシューティカルズ，エルエルシー メニン－ｍｌｌ相互作用の阻害剤
MX392051B (es) 2016-09-14 2025-03-21 Janssen Pharmaceutica Nv Inhibidores espirobiciclicos de la interaccion de menina-mll
US12084462B2 (en) 2016-09-14 2024-09-10 Janssen Pharmaceutica Nv Spiro bicyclic inhibitors of menin-MLL interaction
CA3033020A1 (en) 2016-09-14 2018-03-22 Janssen Pharmaceutica Nv Fused bicyclic inhibitors of menin-mll interaction
JP7142010B2 (ja) 2016-12-15 2022-09-26 ヤンセン ファーマシューティカ エヌ．ベー． メニン－ｍｌｌ相互作用のアゼパン阻害剤
CN110691779B (zh) 2017-03-24 2023-10-10 库拉肿瘤学公司 治疗血液系统恶性肿瘤和尤因肉瘤的方法
US11542248B2 (en) 2017-06-08 2023-01-03 Kura Oncology, Inc. Methods and compositions for inhibiting the interaction of menin with MLL proteins
WO2019060365A1 (en) 2017-09-20 2019-03-28 Kura Oncology, Inc. SUBSTITUTED MÉNINE-MLL INHIBITORS AND METHODS OF USE
US11396517B1 (en) 2017-12-20 2022-07-26 Janssen Pharmaceutica Nv Exo-aza spiro inhibitors of menin-MLL interaction
CN112105621B (zh) 2018-03-30 2024-02-20 住友制药株式会社 光学活性桥型环状仲胺衍生物
CN111936465A (zh) * 2018-03-30 2020-11-13 密歇根大学董事会 作为共价menin抑制剂的哌啶化合物
EP3856173A4 (en) * 2018-09-26 2022-07-06 Kura Oncology, Inc. TREATMENT OF HEMOPATHY MALIGNANCE WITH MENIN INHIBITORS
SG11202101733TA (en) 2018-10-03 2021-03-30 Univ Michigan Regents Small molecule menin inhibitors
US11174263B2 (en) 2018-12-31 2021-11-16 Biomea Fusion, Inc. Inhibitors of menin-MLL interaction
JP7536767B2 (ja) 2018-12-31 2024-08-20 バイオメア フュージョン，インコーポレイテッド メニン－ｍｌｌ相互作用の不可逆的阻害剤
WO2021067215A1 (en) 2019-09-30 2021-04-08 Agios Pharmaceuticals, Inc. Piperidine compounds as menin inhibitors
UA129208C2 (uk) 2019-12-19 2025-02-05 Янссен Фармацевтика Нв Заміщені спіропохідні з прямим ланцюгом
TW202204334A (zh) 2020-04-08 2022-02-01 美商阿吉歐斯製藥公司 Menin抑制劑及治療癌症之使用方法
TW202204333A (zh) 2020-04-08 2022-02-01 美商阿吉歐斯製藥公司 Menin抑制劑及治療癌症之使用方法
EP4334320A1 (en) 2021-05-08 2024-03-13 JANSSEN Pharmaceutica NV Substituted spiro derivatives
KR20240006542A (ko) 2021-05-08 2024-01-15 얀센 파마슈티카 엔브이 치환된 스피로 유도체
EP4337329A4 (en) * 2021-05-12 2025-01-01 Syndax Pharmaceuticals, Inc. COMBINATIONS FOR CANCER TREATMENT
CR20230605A (es) 2021-06-01 2024-05-24 Janssen Pharmaceutica Nv Derivados de fenil-1h-pirrolo[2,3-c]piridina sustituidos
US20250333421A1 (en) 2021-06-03 2025-10-30 Janssen Pharmaceutica Nv Pyridazines or 1,2,4-triazines substituted by spirocyclic amines
IL309359A (en) 2021-06-17 2024-02-01 Janssen Pharmaceutica Nv (r)-n-ethyl-5-fluoro-n-isopropyl-2-((5-(2-(6-((2-methoxyethyl)(methyl)amino)-2-methylhexan-3-yl)-2,6-diazaspiro[3.4]octan-6-yl)-1,2,4-triazin-6-yl)oxy)benzamide besylate salt for the treatment of diseases such as cancer
TW202320796A (zh) 2021-08-11 2023-06-01 美商拜歐米富士恩股份有限公司 用於糖尿病的menin-mll相互作用之共價抑制劑
TW202313004A (zh) 2021-08-20 2023-04-01 美商拜歐米富士恩股份有限公司 Ｍｅｎｉｎ－ｍｌｌ相互作用之不可逆抑制劑的結晶形式
WO2023056589A1 (en) 2021-10-08 2023-04-13 Servier Pharmaceuticals Llc Menin inhibitors and methods of use for treating cancer
EP4525873A1 (en) * 2022-05-17 2025-03-26 Biomea Fusion, Inc. Flt3 combination therapy for cancer and compositions therefor
KR20250109775A (ko) 2022-11-24 2025-07-17 오리존 지노믹스 에스.에이. 암 치료를 위한 lsd1 억제제 및 메닌 억제제의 조합
TW202430528A (zh) 2023-01-18 2024-08-01 美商拜歐米富士恩股份有限公司 Ｎ－［４－［４－（４－嗎啉基）－７ｈ－吡咯並［２，３－ｄ］嘧啶－６－基］苯基］－４－［［３（ｒ）－［（１－氧代－２－丙烯－１－基）氨基］－１－哌啶基］甲基］－２－吡啶甲醯胺的結晶形式作為ｍｅｎｉｎ－ｍｌｌ相互作用的共價抑制劑
CN120987784A (zh) * 2025-10-23 2025-11-21 辽宁鸿港化工有限公司 一种对甲氧基苄胺及其制备方法和用途

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140371239A1 (en) 2013-06-12 2014-12-18 The Regents Of The University Of Michigan Menin-mll inhibitors and methods of use thereof
WO2014200479A1 (en) 2013-06-12 2014-12-18 The Regents Of The University Of Michigan Menin-mll inhibitors and methods of use thereof

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5093330A (en) 1987-06-15 1992-03-03 Ciba-Geigy Corporation Staurosporine derivatives substituted at methylamino nitrogen
WO1998054167A1 (en) 1997-05-28 1998-12-03 Mitsubishi-Tokyo Pharmaceuticals, Inc. Indole compounds
US7576082B2 (en) 2005-06-24 2009-08-18 Hoffman-La Roche Inc. Oxindole derivatives
WO2008070303A2 (en) 2006-10-19 2008-06-12 The University Of Chicago Therapeutics to inhibit mll-menin interaction for treating leukemia
EP2473054B1 (en) 2009-09-04 2017-06-14 The Regents of the University of Michigan Compositions and methods for treatment of leukemia
US8946197B2 (en) 2009-11-16 2015-02-03 Chdi Foundation, Inc. Transglutaminase TG2 inhibitors, pharmaceutical compositions, and methods of use thereof
RU2617643C2 (ru) 2011-05-09 2017-04-25 ФОРМА ТиЭм, ЭлЭлСИ Новые соединения и композиции для ингибирования nampt
BR112015022602A2 (pt) 2013-03-13 2017-07-18 Univ Michigan Regents composições compreendendo compostos de tienopirimidina e tienopiridina e métodos de uso dos mesmos
WO2016040330A1 (en) 2014-09-09 2016-03-17 The Regents Of The University Of Michigan Thienopyrimidine and thienopyridine compounds and methods of use thereof
TWI703150B (zh) 2015-06-04 2020-09-01 美商庫拉腫瘤技術股份有限公司 用於抑制ｍｅｎｉｎ及ｍｌｌ蛋白之交互作用的方法及組合物
US10588907B2 (en) 2015-06-04 2020-03-17 Kura Oncology, Inc. Methods and compositions for inhibiting the interaction of menin with MLL proteins
EP3394064A1 (en) 2015-12-22 2018-10-31 Vitae Pharmaceuticals, Inc. Inhibitors of the menin-mll interaction
SI3429591T1 (sl) 2016-03-16 2023-07-31 Kura Oncology, Inc. Substituirani tieno(2,3-d)pirimidinski derivati kot inhibitorji menin-MLL in postopki uporabe
PH12018501955B1 (en) 2016-03-16 2024-01-24 Kura Oncology Inc Bridged bicyclic inhibitors of menin-mll and methods of use
WO2017192543A1 (en) 2016-05-02 2017-11-09 Regents Of The University Of Michigan Piperidines as menin inhibitors
JP7007302B2 (ja) 2016-06-10 2022-01-24 ヴァイティー ファーマシューティカルズ，エルエルシー メニン－ｍｌｌ相互作用の阻害剤
JP2019529421A (ja) 2016-09-16 2019-10-17 ヴァイティー ファーマシューティカルズ，エルエルシー ｍｅｎｉｎ−ＭＬＬ相互作用の阻害剤
WO2018106818A1 (en) 2016-12-07 2018-06-14 Kura Oncology, Inc. Methods of promoting beta cell proliferation
CN110691779B (zh) 2017-03-24 2023-10-10 库拉肿瘤学公司 治疗血液系统恶性肿瘤和尤因肉瘤的方法
AU2018243586A1 (en) 2017-03-31 2019-10-17 The Regents Of The University Of Michigan Piperidines as covalent menin inhibitors
US11542248B2 (en) 2017-06-08 2023-01-03 Kura Oncology, Inc. Methods and compositions for inhibiting the interaction of menin with MLL proteins
WO2019060365A1 (en) 2017-09-20 2019-03-28 Kura Oncology, Inc. SUBSTITUTED MÉNINE-MLL INHIBITORS AND METHODS OF USE
CN112105621B (zh) 2018-03-30 2024-02-20 住友制药株式会社 光学活性桥型环状仲胺衍生物
EP3856173A4 (en) 2018-09-26 2022-07-06 Kura Oncology, Inc. TREATMENT OF HEMOPATHY MALIGNANCE WITH MENIN INHIBITORS

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140371239A1 (en) 2013-06-12 2014-12-18 The Regents Of The University Of Michigan Menin-mll inhibitors and methods of use thereof
WO2014200479A1 (en) 2013-06-12 2014-12-18 The Regents Of The University Of Michigan Menin-mll inhibitors and methods of use thereof

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
BURM BRIGITTE E A; GREMMEN CHRISTIAAN; WANNER MARTIN J; ET AL，SYNTHESIS OF NEW BRIDGED TETRAHYDRO-Β-CARBOLINES AND SPIRO-FUSED QUINUCLIDINES，TETRAHEDRON，2001年，VOL:57, NR:10，PAGE(S):2039 - 2049，http://dx.doi.org/10.1016/S0040-4020(01)00023-0
HE S; ET AL，HIGH-AFFINITY SMALL MOLECULE INHIBITORS OF THE MENIN-MIXED LINEAGE LEUKEMIA (MLL) 以下備考，JOURNAL OF MEDICINAL CHEMISTRY，2014年01月28日，VOL:57，PAGE(S):1543 - 1556，http://dx.doi.org/10.1021/jm401868d，INTERACTION CLOSELY MIMIC A NATURAL PROTEIN-PROTEIN INTERACTION
KITA Y; ET AL，ENHANCING EFFECTS OF SALT FORMATION ON CATALYTIC ACTIVITY AND ENANTIOSELECTIVITY FOR 以下備考，CHEMISTRY - A EUROPEAN JOURNAL，2014年11月28日，VOL:21，PAGE(S):1915 - 1927，ASYMETRIC HYDROGENATION OF ISOQUINOLINIUM SALTS BY DINUCLEAR HALIDE-BRIDGED IRIDIUM 以下省略
PITTA B R; ET AL，METALATED NITRILE AND ENOLATE CHLORINATIONS，ORGANIC LETTERS，2010年05月18日，VOL:12, NR:12，PAGE(S):2810 - 2813，http://dx.doi.org/10.1021/ol100897y
PRAT L; ET AL，SYNTHESIS OF N-METHYL-4-PYRIDYL-1,2,3,4-TETRAHYDROISOQUINOLINES VIA A PICTET-SPENGLER CYCLISATION，JOURNAL OF HETEROCYCLIC CHEMISTRY，2000年07月，VOL:37，PAGE(S):767 - 771，https://onlinelibrary.wiley.com/doi/abs/10.1002/jhet.5570370417
SENTER T; ET AL，PROGRESS TOWARDS SMALL MOLECULE MENIN-MIXED LINEAGE LEUKEMIA (MLL) INTERACTION INHIBITORS 以下備考，BIOORGANIC AND MEDICINAL CHEMISTRY LETTERS，2015年04月25日，VOL:25，PAGE(S):2720 - 2725，http://dx.doi.org/10.1016/j.bmcl.2015.04.026，WITH IN VIVO UTILITY

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020515571A (ja) * 2017-03-31 2020-05-28 ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン 共有結合性メニン阻害剤としてのピペリジン

Also Published As

Publication number Publication date
CN109415337B (zh) 2022-01-18
WO2017192543A1 (en) 2017-11-09
BR112018072570A2 (pt) 2019-02-19
CA3022868A1 (en) 2017-11-09
KR20190015275A (ko) 2019-02-13
US20210198237A1 (en) 2021-07-01
IL262697A (en) 2018-12-31
JP2019514950A (ja) 2019-06-06
MX384087B (es) 2025-03-14
US10899738B2 (en) 2021-01-26
SG11201809714TA (en) 2018-11-29
ES2899936T3 (es) 2022-03-15
IL262697B (en) 2021-04-29
IL281182A (en) 2021-04-29
MX2018013433A (es) 2019-07-18
AU2017259436B2 (en) 2021-08-26
AU2017259436A1 (en) 2018-12-20
CN109415337A (zh) 2019-03-01
EP3452461B1 (en) 2021-09-08
EP3452461A1 (en) 2019-03-13
US20190152947A1 (en) 2019-05-23

Similar Documents

Publication Publication Date Title
JP6991585B2 (ja) メニン阻害剤としてのピペリジン
JP7037500B2 (ja) Ｍｄｍ２タンパク質分解剤
JP7072519B2 (ja) Ｂｅｔタンパク質分解剤
CN110062759B (zh) 作为bet蛋白降解剂的稠合的1,4-氧氮杂䓬
JP2020515571A (ja) 共有結合性メニン阻害剤としてのピペリジン
JP2021519785A (ja) 共有結合性メニン阻害剤としてのピペリジン化合物
CN112119080B (zh) 作为lsd-1抑制剂的咪唑并[4,5-c]吡啶化合物
KR20210072787A (ko) 저분자 메닌 억제제
CN120712252A (zh) 包含sos1抑制剂和抗癌药物的用于治疗癌症的药物组合物
HK40006016B (en) Piperidines as menin inhibitors
HK40006016A (en) Piperidines as menin inhibitors
HK40041770B (en) Imidazo[4,5-c]pyridine compounds as lsd-1 inhibitors
HK40041770A (en) Imidazo[4,5-c]pyridine compounds as lsd-1 inhibitors

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20181128

RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7423

Effective date: 20191218

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20191218

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200428

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200428

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20210304

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210312

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210614

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20211101

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20211201

R150 Certificate of patent or registration of utility model

Ref document number: 6991585

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

LAPS Cancellation because of no payment of annual fees